Cara Therapeutics Inc (NASDAQ:CARA)

29.18
Delayed Data
As of Apr 09
 +1.71 / +6.22%
Today’s Change
12.30
Today|||52-Week Range
29.65
+92.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Contact Information

CARA Therapeutics, Inc.
4 Stamford Plaza
Stamford Connecticut 06902
P:(203) 406-3700
Investor Relations:

Employees

Shareholders

Other institutional40.36%
Mutual fund holders26.24%
Individual stakeholders19.49%

Top Executives

Derek T. ChalmersPresident, Chief Executive Officer & Director
Thomas ReillyChief Financial & Accounting Officer
Frèdèrique MenzaghiChief Scientific Officer, Senior VP-R&D
Joana GoncalvesChief Medical Officer
Scott M. TerrillionSecretary & Chief Compliance Officer